Author:
Hao Chen,Yubao Cui,Rongfei Zhu
Abstract
Asthma was a chronic inflammatory airway disease which characterized by complex pathogenesis, various clinical manifestations and severity. Blood biomarkers have been used to evaluate the severity of the disease, predict the efficacy and prognosis. Currently, some incredible progress in most of the research on biomarkers for asthma have achieved, including cell, antibodies, cytokines, chemokines, proteins and non-coding RNAs. We reviewed the application of these biomarkers in diagnosis, treatment, prognosis monitoring and phenotypic identification of asthma, in order to improve clinicians’ understanding of asthma biomarkers.
Reference112 articles.
1. Cloutier MM, Dixon AE, Krishnan JA, Lemanske RJ, Pace W, Schatz M. Managing Asthma in Adolescents and Adults: 2020 Asthma Guideline Update From the National Asthma Education and Prevention Program. JAMA. 2020;324:2301-2317
2. Huang K, Yang T, Xu J, Yang L, Zhao J, Zhang X, et al. Prevalence, risk factors, and management of asthma in China: A national cross-sectional study. Lancet. 2019;394:407-418
3. Lishen S, Qianlan Z, Yunxiao S. The Mechanism, testing, specific immunotherapy and anti-IgE therapy for allergic respiratory diseases in children. International Journal of Pediatrics. 2020;47:823-827
4. Mendes FC, Paciencia I, Ferreira AC, Martins C, Rufo JC, Silva D, et al. Development and validation of exhaled breath condensate microRNAs to identify and endotype asthma in children. PLoS One. 2019;14:e224983
5. Agache I, Akdis CA. Precision medicine and phenotypes, endotypes, genotypes, regiotypes, and theratypes of allergic diseases. The Journal of Clinical Investigation. 2019;129:1493-1503